New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 30, 2013
06:57 EDTBCRXBioCryst receives additional NIAID funding of $2.5M for BCX4430 development
BioCryst announced that the National Institute of Allergy and Infectious Diseases has exercised an option to conduct the investigational new drug enabling program and to submit an IND. This option represents an additional $2.5M to BioCryst in order to advance the development of BCX4430 as a treatment for Marburg virus disease. The total funding could be up to $22M over five years and advance the program through Phase 1 trials, if all contract options are exercised. The goals of this contract are to file IND applications for intravenous and intramuscular BCX4430 for the treatment of Marburg virus disease, and to conduct Phase 1 human clinical trials.
News For BCRX From The Last 14 Days
Check below for free stories on BCRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
09:27 EDTBCRXBioCryst management to meet with Needham
Subscribe for More Information
April 14, 2014
10:02 EDTBCRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:08 EDTBCRXBioCryst initiated with an Outperform at Brinson Patrick
Target $15.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use